State Street SPDR S&P Biotech ETF
$155.88−5.99 (−3.70%)
- Expense ratio
- 0.35%
- Fund size
- $10.4B
- 1Y return
- +67.1%
- Yield · Last 12 months
- 0.34%
- Holdings
- 165
- Volume · 30D
- 8.7M sh
- NAV per share
- $158.22
- 52W range
The ETF.net XBI Grade
Score 81 of 100 sits in the A band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.AScore 81Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.AScore 85Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 55Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.AScore 96Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.AScore 88Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 89Category rank
Our read on XBI
ABiotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.
The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.
Why people hold it
- Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
- 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
- Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
- A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.
Worth knowing
- Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comindexes.nasdaqomx.com
- Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
- One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com
XBI Holdings
- Stocks
- 165
- 16%
- TWST
Sectors
- Health Care99.3%
- Financials0.7%
Geography
- United States94.79%
- Switzerland1.51%
- Ireland1.46%
- United Kingdom1.38%
- Netherlands0.87%
XBI Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
XBI$16,706
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | XBI |
|---|---|
| Year to date | +32.9% |
| 1 month | −2.3% |
| 3 months | +11.0% |
| 1 year | +67.1% |
| 3 years | +30.7% |
| 5 years | +4.5% |
| 10 years | +9.1% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | XBI |
|---|---|---|
| 2026 YTD | +32.9% | |
| 2025 | +35.9% | |
| 2024 | +1.0% | |
| 2023 | +7.6% | |
| 2022 | −25.9% | |
| 2021 | −20.5% | |
| 2020 | +48.3% |
XBI in the news
XBI Dividends
- 0.34%
- $0.54
- $0.14 per share
- Twice a year
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Jun 22, 2026 | Jun 24, 2026 | $0.14 |
| Dec 22, 2025 | Dec 24, 2025 | $0.41 |
| Sep 22, 2025 | Sep 24, 2025 | $0.03 |
| Jun 23, 2025 | Jun 25, 2025 | $0.0073 |
| Mar 24, 2025 | Mar 26, 2025 | $0.0053 |
| Dec 23, 2024 | Dec 26, 2024 | $0.0027 |
| Sep 23, 2024 | Sep 25, 2024 | $0.02 |
| Jun 24, 2024 | Jun 26, 2024 | $0.11 |
| Dec 18, 2023 | Dec 21, 2023 | $0.01 |
| Jun 20, 2023 | Jun 23, 2023 | $0.0026 |
| Mar 22, 2021 | Mar 25, 2021 | $0.04 |
| Dec 21, 2020 | Dec 24, 2020 | $0.18 |
XBI Risk
- 26.1%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.88
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −53.2%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.10
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
XBI Cost
0.35%
XBI0.35%
- The middle half of Biotech & Genomics funds
- Median 0.47%
1 of the 15 Biotech & Genomics funds charge less.